GlassScriptPhysician profile
Tracy A Haines
NPI 1316129356
$6,260.61
in general payments reported to CMS, 2019-2025
28 companies · $1,112 in 2025
The $1,112 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $850 · 2020: $290 · 2021: $428 · 2022: $1,164 · 2023: $1,408 · 2024: $1,008 · 2025: $1,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,228 · Education: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,228.29 |
| Education | $299.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,528.70 | 2019-2025 | |
| Janssen Biotech, INC. | $892.10 | 2020-2025 | Tremfya, Stelara, Simponi |
| Novartis Pharmaceuticals Corporation | $538.82 | 2019-2025 | |
| Genzyme Corporation | $439.79 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $398.35 | 2019-2023 | Jublia, Arazlo |
| Regeneron Healthcare Solutions, INC. | $384.66 | 2019-2025 | Dupixent |
| Leo Pharma INC. | $374.07 | 2021-2025 | Adbry, Anzupgo |
| Incyte Corporation | $248.29 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $182.51 | 2020-2023 | Winlevi, Odomzo, Blu-U |
| Ucb, INC. | $166.74 | 2022-2024 | Cimzia, Bimzelx |
| Organon LLC | $123.72 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $112.22 | 2022-2024 | Sotyktu |
| Amgen INC. | $110.71 | 2019-2023 | Otezla |
| Pfizer INC. | $102.33 | 2021-2025 | |
| Lilly USA, LLC | $100.20 | 2022-2024 | Olumiant, Taltz |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $84.07 | 2019-2023 | Aklief |
| Arcutis Biotherapeutics, INC. | $78.28 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $58.99 | 2023-2024 | Vtama |
| Journey Medical Corporation | $58.59 | 2023-2025 | |
| Almirall LLC | $50.81 | 2019-2023 | Klisyri |
| Dusa Pharmaceuticals, INC. | $47.92 | 2019 | |
| Celgene Corporation | $37.33 | 2019 | |
| Vyne Pharmaceuticals INC. | $36.27 | 2020 | |
| Epi Health, LLC | $33.12 | 2019 | |
| Dermira, INC. | $29.30 | 2019-2020 | |
| Organogenesis INC. | $21.19 | 2021 | |
| Mission Pharmacal Company | $12.46 | 2019 | |
| Kerecis Limited | $9.07 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Haines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.